US FDA’s flagship expedited review programs – the breakthrough therapy designation and its younger cousin, the biologics-focused regenerative medicine advanced therapy designation – have added new designations at a slower pace than the peak a few years ago.
Those designations that have been announced this year, however, illustrate the widening scope of the programs beyond the oncologics and...